Your browser doesn't support javascript.
loading
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz, Christoph; Bigler, Martin; von Moos, Roger; Bernhard, Jürg; Matter-Walstra, Klazien; Wicki, Andreas; Zaman, Khalil; Anchisi, Sandro; Küng, Marc; Na, Kyung-Jae; Bärtschi, Daniela; Borner, Markus; Rordorf, Tamara; Rauch, Daniel; Müller, Andreas; Ruhstaller, Thomas; Vetter, Marcus; Trojan, Andreas; Hasler-Strub, Ursula; Cathomas, Richard; Winterhalder, Ralph.
Afiliación
  • Rochlitz C; Department of Oncology, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland. Christoph.Rochlitz@usb.ch.
  • Bigler M; SAKK Coordinating Center, Bern, Switzerland.
  • von Moos R; Department of Oncology, Kantonsspital Graubünden, Chur, Switzerland.
  • Bernhard J; International Breast Cancer Study (IBCSG) and Inselspital, Bern University Hospital, Bern, Switzerland.
  • Matter-Walstra K; SAKK Coordinating Center, Bern, Switzerland and European Center for Pharmaceutical Medicine, University Basel, Basel, Switzerland.
  • Wicki A; Department of Oncology, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
  • Zaman K; Department of Oncology, University Hospital Lausanne, Lausanne, Switzerland.
  • Anchisi S; Department of Oncology, Hospital of Valais, Sion, Switzerland.
  • Küng M; Department of Oncology, Kantonsspital Fribourg, Fribourg, Switzerland.
  • Na KJ; SAKK Coordinating Center, Bern, Switzerland.
  • Bärtschi D; Present Address: Novartis Pharma, Stein, Switzerland.
  • Borner M; SAKK Coordinating Center, Bern, Switzerland.
  • Rordorf T; Department of Oncology, Spitalzentrum Biel, Biel, Switzerland.
  • Rauch D; Department of Oncology, University Hospital Zürich, Zürich, Switzerland.
  • Müller A; Department of Oncology, Spital STS, Thun, Switzerland.
  • Ruhstaller T; Department of Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
  • Vetter M; Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Trojan A; Department of Oncology, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
  • Hasler-Strub U; Department of Oncology, OnkoZentrum Zürich, Zürich, Switzerland.
  • Cathomas R; Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Winterhalder R; Department of Oncology, Kantonsspital Graubünden, Chur, Switzerland.
BMC Cancer ; 16(1): 780, 2016 10 10.
Article en En | MEDLINE | ID: mdl-27724870
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article